ARCHIVES

Phase III Regorafenib Trial Meets Endpoint Improving Progression-Free Survival

This article is from The Cancer Letter archive.

Vol. 35 No. 4 | April 27, 2012

Download PDF Visit The Full Archive

Related Articles

Joseph Jacobs, New Head Of alternative Medicine Office, Vows To ‘Talk Bluntly’

December 11, 1992

Investigators Plan To Interview DeVita, Mendelsohn on C225 Development

July 5, 2002

Capitated Oncology Becomes Marketplace Reality Wit Plan By Companies

January 14, 1994

DCAB Board Okays One Contract Concept, Sends Another Back to Drawing Board

May 22, 1981

HCRA Response On DRGs and Clinical Research Threat Called A “Stone Wall,” Legislative Remedy Sought

July 27, 1984

McCormick President-Elect of AACR; Garber To Start Term As President

March 25, 2011